Comparison
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 vs 17q24 2 Microdeletion Syndrome C5680185
Clinical comparison between 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome and 17q24 2 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
A severe mitochondrial disorder affecting the brain, hearing, and energy metabolism. It causes progressive neurological decline, hearing loss, and metabolic problems. Management requires intensive supportive care.
17q24 2 Microdeletion Syndrome C5680185
A rare genetic disorder caused by deletion of genetic material on chromosome 17. Individuals may have developmental delays, facial features, and other medical issues. Care is supportive and multidisciplinary.
6 comparison axes
Onset
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
0-5
17q24 2 Microdeletion Syndrome C5680185
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
severe
17q24 2 Microdeletion Syndrome C5680185
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
Chronic
17q24 2 Microdeletion Syndrome C5680185
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
No
17q24 2 Microdeletion Syndrome C5680185
No
Different transmission
Body System
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
metabolic
17q24 2 Microdeletion Syndrome C5680185
congenital
Same/different system
Category
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
metabolic
17q24 2 Microdeletion Syndrome C5680185
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-with-deafness-encephalopathy-and-leigh-like-syndrome-C4040739 and 17q24-2-microdeletion-syndrome-C5680185 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 | 17q24 2 Microdeletion Syndrome C5680185 | Discriminating power |
|---|---|---|---|
| Hearing loss | Sensorineural hearing loss is a described core feature, often with progressive neurologic disease. | Hearing loss is not established as a defining feature from the supplied description. | High |
| Neurologic course | Progressive encephalopathy and Leigh-like brain involvement may occur. | Developmental delay may occur; a progressive metabolic encephalopathy is not established. | High |
| Dysmorphic features | Characteristic facial features are not established by the supplied source. | Facial differences may be present, but the specific pattern is not defined here. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 when
Infant or young child with hearing loss and neurologic decline
This combination fits the described mitochondrial phenotype better than a nonspecific microdeletion.
Moderate
Suspected energy-metabolism disorder
Metabolic and mitochondrial features point toward the left condition.
Moderate
Leigh-like imaging or clinical pattern
Leigh-like involvement is specifically described for the left condition.
Moderate
Choose 17q24 2 Microdeletion Syndrome C5680185 when
Developmental delay with congenital or dysmorphic clues
A chromosomal deletion is more consistent with this presentation.
Moderate
No clear metabolic crisis or hearing-loss pattern
Absence of the left phenotype makes the microdeletion relatively more plausible, but does not confirm it.
Low
Family or clinician suspects a copy-number variant
The right condition is defined by missing chromosome 17 material.
High
How key tests differ
| Test | 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 | 17q24 2 Microdeletion Syndrome C5680185 | Interpretation |
|---|---|---|---|
| Urine organic acids | 3-Methylglutaconic aciduria may be found; no cutoff is supplied. | No characteristic organic-acid result is established. | An abnormal result supports, but does not alone diagnose, the left disorder. |
| Chromosomal microarray | A 17q24.2 deletion is not the described cause. | May identify a 17q24.2 microdeletion. | A confirmed deletion supports the right diagnosis after clinical correlation. |
| Brain imaging and hearing assessment | May show Leigh-like changes and hearing impairment. | No specific imaging or hearing pattern is established. | Results help phenotype the patient but require specialist review. |
Prognosis comparison
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
- Outcome
- Potentially severe progressive neurologic disease; exact survival is not established.
- Factors
- Hearing loss, encephalopathy, metabolic instability, and available supportive care.
17q24 2 Microdeletion Syndrome C5680185
- Outcome
- Often described as moderate, but individual outcome is not established.
- Factors
- Extent of developmental delay and associated medical issues.
Time frame: Chronic course; left onset is described in early childhood, while right timing is not fully specified.
Precise prognosis cannot be inferred from these sparse descriptions.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic deterioration | Progressive decline is described and may be severe. Developmental impairment may occur; progression is not established. Trajectory should be judged individually. |
| Hearing impairment | Hearing loss is a major described feature. Not established as characteristic. Audiology is especially relevant when the left disorder is suspected. |
| Associated medical issues | Metabolic problems may require intensive supportive care. Other medical issues may occur, but specifics are not supplied. Neither description establishes exact complication rates. |
Patient education highlights
- HighSpecialist care
Both are rare and need genetics and relevant specialty follow-up; urgent care is needed for acute neurologic or metabolic change.
- HighDiagnosis versus test result
An abnormal metabolite or genetic finding needs confirmation and clinical interpretation before being treated as a diagnosis.
- MediumSupportive management
Care is supportive and individualized; no treatment dose or cure is established by this comparison.